News and Announcements
JustKapital Expected to Deliver Over $5.6m EBITDA in FY17
- Published May 24, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
As a result of continuing growth in the Disbursement Funding Division, the Board of Directors of JustKapital Limited is pleased to announce the Disbursement Funding Division is now expected to deliver more than $5.4 million EBITDA in FY2017.
KEY TAKEAWAYS:
- The Short-Term Funding Division, which provides finance to law firms for a duration of less than 12 months, is expected to deliver an additional $0.2 million EBITDA in FY2017.
- JustKapital has developed into a diversified provider of financing solutions for law firms, these two divisions have now been merged and are now referred to as “JustKapital Finance” by the Group.
- Accordingly combined EBITDA for JustKapital Finance is expected to exceed $5.6 million for FY2017.
Due to the nature of litigation it is not possible to predict the timing of the completion of a case with accuracy. Therefore, it is not possible to provide a forecast for the Group’s Litigation Funding Division. The Group continues to expect that at least one case will conclude in FY2017.
Philip Kapp, founder and Executive Chairman noted that since JustKapital acquired the business of Macquarie Medico Legal in January 2016, JustKapital Finance has diversified its product offering from funding medical reports into general disbursements funding and short term finance for the legal industry. Revenue is on track to increase by 53% (year on year). In addition, the gross disbursement funding receivables has almost doubled to $30 million.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
